Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.
NCT03007329 on ClinicalTrials.gov · last registry update 2022-04-15
A small phase 4 — 34 participants, against a typical 75. The sponsor logged completion for 26 November 2019. Primary outcome, as filed: change in hepatic lipid content measured with magnetic resonance spectroscopy in %. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Medical University of Vienna
- Sponsor type
- Other
- Enrollment
- 34
- Started
- 2017-03-08
- Primary completion
- 2019-11-26 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
change in hepatic lipid content measured with magnetic resonance spectroscopy in %
Conditions studied
Steatosis, Liver · Type2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.